Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

PRIMARY OBJECTIVES:

I. To evaluate the toxicity and determine recommended phase II dose of the combination of
docetaxel and selinexor. (Phase I) II. To evaluate the efficacy as measured by progression
free survival (PFS) of docetaxel and selinexor in patients with recurrent/metastatic
squamous cell lung cancer. (Phase I/II)

SECONDARY OBJECTIVES:

I. To evaluate the objective tumor response rate as determined by radiographic response.

II. To evaluated the disease control rate (complete response, partial responses, and stable
disease).

III. To evaluate the overall survival (OS). IV. To evaluate the safety and tolerability of
single agent selinexor.

TERTIARY OBJECTIVES:

I. Lung cancer genomics sequencing panel. II. Tumor biopsy (baseline and cycle 2). III.
Plasma cytokine analysis, peripheral blood ribonucleic acid (RNA) analysis.

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

Patients receive docetaxel intravenously (IV) on day 1 and selinexor orally (PO) twice daily
(BID) on days 1, 3, 7, 9, 13, and 15. Courses repeat every 21 days in the absence of disease
progression or unacceptable toxicity.

After completion of study treatment, patients are followed up monthly for 3 months, every 3
months for 9 months, and then every 6 months thereafter.

Inclusion Criteria:

- Written informed consent in accordance with federal, local, and institutional
guidelines

- Patients with recurrent or metastatic squamous cell carcinoma of the lung - diagnosis
must be histologically confirmed

- Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at
the time of study entry

- Objective evidence of disease progression on study entry

- Prior systemic anticancer therapy: Patients will have received at least 1
platinum-based chemotherapy regimen, but no more than 2 cytotoxic chemotherapy
regimens in the setting of recurrent or metastatic disease; the regimen(s) may have
included biological, molecularly targeted or immune therapies; adjuvant chemotherapy
is considered 1 cytotoxic chemotherapy regimen if the last administration occurred <
1 year prior to entry

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

- Absolute neutrophil count (ANC) > 1500/mm^3

- Platelets count > 100,000 mm^3 and less than 1,000,000 mm^3

- Total bilirubin < 2 times the upper limit of normal (ULN) (except patients with
Gilbert's syndrome who must have a total bilirubin of < 3 times ULN)

- Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological
and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable;
patients with > 3 liver metastases at enrollment will be excluded

- Estimated creatinine clearance of >= 30 mL/min, calculated using the formula of
Cockcroft and Gault

- Amylase =< 1.5 x ULN

- Lipase =< 1.5 x ULN

- Alkaline phosphatase limit =< 2.5 x ULN

- Female patients of child-bearing potential must agree to use dual methods of
contraception and have a negative serum pregnancy test at screening; male patients
must use an effective barrier method of contraception if sexually active with a
female of child-bearing potential throughout the study and for three months following
the last dose of selinexor

- Resolution to grade =< 1 by National Cancer Institute Common Terminology Criteria for
Adverse Events version 4.03 (CTCAE v4.03) of all clinically significant toxic effects
of prior anti-cancer therapy (with the exception neuropathy, which may be =< grade 2
within 14 days prior to cycle 1 day 1)

Exclusion Criteria:

- Patients who are pregnant or lactating

- Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =< 2 weeks
prior to cycle 1 day 1

- Prior treatment with selective inhibitor of nuclear export (SINE) inhibitor

- Major surgery within four weeks before cycle 1, day 1

- Unstable cardiovascular function:

- Electrocardiography (ECG) abnormalities requiring treatment, or

- Congestive heart failure (CHF) of New York Heart Association (NYHA) class >= 3

- Myocardial infarction (MI) within 3 months

- Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals
within one week prior to first dose; patients with controlled infection or on
prophylactic antibiotics are permitted in the study

- Known to be human immunodeficiency virus (HIV) seropositive

- Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C
virus (HCV) RNA or hepatitis B surface antigen (HBsAg) (hepatitis B virus [HBV]
surface antigen)

- Any underlying condition that would significantly interfere with the absorption of an
oral medication

- Patients with markedly decreased visual acuity

- Serious psychiatric or medical conditions that could interfere with treatment

- Participation in an investigational anti-cancer study =< 3 weeks prior to cycle day 1

- Concurrent therapy with approved or investigational anticancer therapeutic other than
steroids

- Patients with coagulation problems and active bleeding in the last month (peptic
ulcer, epistaxis, spontaneous bleeding)

- Uncontrolled brain metastases; patients with brain metastases are permitted if they
have received appropriate therapy and demonstrated control of the brain metastases
following therapy; patients with known brain metastases will require magnetic
resonance imaging (MRI) brain to demonstrate disease control prior to enrollment
(lack of symptom progression for two weeks off therapeutic doses of steroids,
excluding chronic steroids used for control of chronic obstructive pulmonary disease
[COPD])

- Renal failure requiring hemodialysis or peritoneal dialysis

- Patients with significantly diseased or obstructed gastrointestinal tract,
malabsorption, uncontrolled vomiting or diarrhea or inability to swallow oral
medications

- Patients who are severely underweight in the opinion of the investigator

- Prior cancer diagnosis is allowed if patient is disease-free for >= 3 years, or
disease free for < 3 years for treated basal cell/squamous cell skin cancer or in
situ cervical cancer